

INCOME STATEMENT
Year ended 31st December 2006

	2006 £m	2006 \$m
	<u> </u>	<u> </u>
Turnover:		
Pharmaceuticals	20,078	37,144
Consumer Healthcare	3,147	5,822
	<u> </u>	<u> </u>
TURNOVER	23,225	42,966
Cost of sales	(5,010)	(9,269)
	<u> </u>	<u> </u>
Gross profit	18,215	33,697
Selling, general and administration	(7,257)	(13,425)
Research and development	(3,457)	(6,395)
Other operating income	307	568
	<u> </u>	<u> </u>
Operating profit:		
Pharmaceuticals	7,125	13,181
Consumer Healthcare	683	1,264
	<u> </u>	<u> </u>
OPERATING PROFIT	7,808	14,445
Finance income	287	531
Finance expense	(352)	(651)
Share of after tax profits of joint ventures and associates	56	104
	<u> </u>	<u> </u>
PROFIT BEFORE TAXATION	7,799	14,429
Taxation	(2,301)	(4,257)
	<u> </u>	<u> </u>
PROFIT AFTER TAXATION FOR THE PERIOD	5,498	10,172
	<u> </u>	<u> </u>
Profit attributable to minority interests	109	202
Profit attributable to shareholders	5,389	9,970
	<u> </u>	<u> </u>
	5,498	10,172
	<u> </u>	<u> </u>
EARNINGS PER SHARE	95.5p	176.7
	<u> </u>	<u> </u>
Diluted earnings per share	94.5p	174.8
	<u> </u>	<u> </u>

US dollar amounts shown above are a convenience translation of the sterling amounts.

INCOME STATEMENT
Three months ended 31st December 2006

	Q4 2006 £m	Q4 2006 \$m
Turnover:		
Pharmaceuticals	5,136	9,950
Consumer Healthcare	823	1,592
TURNOVER	5,959	11,542
Cost of sales	(1,445)	(2,781)
Gross profit	4,514	8,761
Selling, general and administration	(1,934)	(3,737)
Research and development	(980)	(1,887)
Other operating income	100	191
Operating profit:		
Pharmaceuticals	1,501	2,945
Consumer Healthcare	199	383
OPERATING PROFIT	1,700	3,328
Finance income	83	160
Finance expense	(86)	(167)
Share of after tax profits of joint ventures and associates	13	26
PROFIT BEFORE TAXATION	1,710	3,347
Taxation	(505)	(988)
PROFIT AFTER TAXATION FOR THE PERIOD	1,205	2,359
Profit attributable to minority interests	24	47
Profit attributable to shareholders	1,181	2,312
EARNINGS PER SHARE	21.0p	41.1
Diluted earnings per share	20.8p	41.0

US dollar amounts shown above are a convenience translation of the sterling amounts.

PHARMACEUTICAL TURNOVER
Year ended 31st December 2006

	Total £m	USA £m	Europe £m	ROW £m	Total US\$m	USA US\$m	Europe US\$m	ROW US\$m
RESPIRATORY	4,995	2,461	1,697	837	9,240	4,553	3,139	1,548
<i>Seretide/Advair</i>	3,313	1,870	1,133	310	6,129	3,459	2,096	574
<i>Flixotide/Flovent</i>	659	298	173	188	1,219	551	320	348
<i>Serevent</i>	291	86	140	65	538	159	259	120
<i>Flixonase/Flonase</i>	311	184	51	76	575	340	94	141
CENTRAL NERVOUS SYSTEM	3,642	2,588	595	459	6,738	4,788	1,101	849
<i>Seroxat/Paxil</i>	620	175	149	296	1,147	323	276	548
<i>Paxil IR</i>	448	19	149	280	829	35	276	518
<i>Paxil CR</i>	172	156	-	16	318	288	-	30
<i>Wellbutrin</i>	900	882	2	16	1,665	1,632	4	29
<i>Wellbutrin IR, SR</i>	102	89	2	11	189	165	4	20
<i>Wellbutrin XL</i>	798	793	-	5	1,476	1,467	-	9
<i>Imigran/Imitrex</i>	711	551	118	42	1,315	1,019	218	78
<i>Lamictal</i>	996	765	175	56	1,843	1,415	324	104
<i>Requip</i>	268	176	81	11	496	326	150	20
ANTI-VIRALS	2,827	1,354	855	618	5,230	2,505	1,582	1,143
HIV	1,515	700	621	194	2,803	1,295	1,149	359
<i>Combivir</i>	528	238	217	73	977	441	401	135
<i>Trizivir</i>	268	141	113	14	496	261	209	26
<i>Epivir</i>	202	69	90	43	374	127	167	80
<i>Ziagen</i>	117	48	41	28	216	88	76	52
<i>Agenerase, Lexiva</i>	131	74	48	9	242	136	89	17
<i>Epzicom/Kivexa</i>	241	125	97	19	446	232	179	35
Herpes	965	610	144	211	1,785	1,129	266	390
<i>Valtrex</i>	845	600	109	136	1,563	1,109	202	252
<i>Zovirax</i>	120	10	35	75	222	19	65	138
<i>Zeffix</i>	162	13	23	126	300	24	43	233
<i>Relenza</i>	91	-	62	29	168	-	114	54
METABOLIC	1,875	1,277	252	346	3,468	2,362	466	640
<i>Avandia</i>	1,399	1,068	125	206	2,588	1,976	231	381
<i>Avandamet</i>	204	86	92	26	377	159	170	48
<i>Avandaryl</i>	42	40	-	2	78	74	-	4
<i>Bonviva/Boniva</i>	95	83	12	-	176	154	22	-
VACCINES	1,692	465	709	518	3,130	860	1,312	958
<i>Hepatitis</i>	479	161	227	91	886	298	420	168
<i>Influenza</i>	170	91	36	43	315	168	67	80
<i>Infanrix/Pediarix</i>	511	172	281	58	945	318	520	107
<i>Boostrix</i>	60	41	15	4	111	76	28	7
CARDIOVASCULAR AND UROGENITAL	1,636	1,072	395	169	3,027	1,983	731	313
<i>Coreg</i>	779	773	-	6	1,441	1,430	-	11
<i>Levitra</i>	43	41	1	1	80	76	2	2
<i>Avodart</i>	216	131	69	16	400	242	128	30
<i>Arixtra</i>	58	32	23	3	107	58	43	6
<i>Fraxiparine</i>	209	-	179	30	387	-	331	56
ANTI-BACTERIALS	1,369	217	628	524	2,533	402	1,162	969
<i>Augmentin</i>	570	94	268	208	1,055	174	496	385
<i>Zinnat/Ceftin</i>	164	12	82	70	303	21	152	130
ONCOLOGY AND EMESIS	1,069	836	153	80	1,978	1,547	283	148
<i>Zofran</i>	847	679	107	61	1,567	1,256	198	113
<i>Hycamtin</i>	113	72	34	7	209	133	63	13
OTHER	973	83	263	627	1,800	153	487	1,160
<i>Zantac</i>	232	72	52	108	429	133	96	200
	20,078	10,353	5,547	4,178	37,144	19,153	10,263	7,728

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

PHARMACEUTICAL TURNOVER
Three months ended 31st December 2006

	Total £m	USA £m	Europe £m	ROW £m	Total US\$m	USA US\$m	Europe US\$m	ROW US\$m
RESPIRATORY	1,269	616	433	220	2,459	1,195	839	425
<i>Seretide/Advair</i>	862	493	293	76	1,668	953	567	148
<i>Flixotide/Flovent</i>	172	79	42	51	333	152	82	99
<i>Serevent</i>	74	22	33	19	143	43	64	36
<i>Flixonase/Flonase</i>	48	17	11	20	96	36	21	39
CENTRAL NERVOUS SYSTEM	915	660	137	118	1,774	1,279	267	228
<i>Seroxat/Paxil</i>	163	49	35	79	316	94	69	153
<i>Paxil IR</i>	113	3	35	75	220	6	69	145
<i>Paxil CR</i>	50	46	-	4	96	88	-	8
<i>Wellbutrin</i>	212	208	-	4	412	405	-	7
<i>Wellbutrin IR, SR</i>	25	22	-	3	48	43	-	5
<i>Wellbutrin XL</i>	187	186	-	1	364	362	-	2
<i>Imigran/Imitrex</i>	174	138	25	11	338	267	49	22
<i>Lamictal</i>	257	204	39	14	498	394	76	28
<i>Requip</i>	76	52	21	3	146	100	41	5
ANTI-VIRALS	706	333	210	163	1,370	647	408	315
HIV	360	168	146	46	701	327	284	90
<i>Combivir</i>	119	56	48	15	232	110	93	29
<i>Trizivir</i>	61	32	25	4	120	63	49	8
<i>Epivir</i>	43	15	18	10	85	29	36	20
<i>Ziagen</i>	28	12	10	6	54	22	20	12
<i>Agenerase, Lexiva</i>	34	19	12	3	65	36	23	6
<i>Epzicom/Kivexa</i>	69	33	29	7	133	65	55	13
Herpes	242	154	36	52	469	299	69	101
<i>Valtrex</i>	212	150	27	35	411	290	53	68
<i>Zovirax</i>	30	4	9	17	58	8	18	32
<i>Zeffix</i>	42	3	6	33	82	6	12	64
<i>Relenza</i>	37	-	22	15	70	-	41	29
METABOLIC	474	321	69	84	918	622	133	163
<i>Avandia</i>	324	246	30	48	631	480	58	93
<i>Avandamet</i>	68	32	27	9	130	61	52	17
<i>Avandaryl</i>	14	14	-	-	27	27	-	-
<i>Bonviva/Boniva</i>	34	29	5	-	65	56	9	-
VACCINES	527	162	200	165	1,010	309	386	315
Hepatitis	128	43	60	25	247	83	116	48
Influenza	107	59	23	25	200	110	43	47
<i>Infanrix/Pediarix</i>	136	47	72	17	263	91	140	32
<i>Boostrix</i>	18	13	5	-	35	25	10	-
CARDIOVASCULAR AND UROGENITAL	421	281	101	39	816	543	195	78
<i>Coreg</i>	199	198	-	1	386	384	-	2
<i>Levitra</i>	12	12	-	-	23	23	-	-
<i>Avodart</i>	61	36	19	6	118	69	37	12
<i>Arixtra</i>	21	12	7	2	40	22	14	4
<i>Fraxiparine</i>	53	-	44	9	103	-	85	18
ANTI-BACTERIALS	354	57	164	133	686	111	318	257
<i>Augmentin</i>	145	25	67	53	281	48	130	103
<i>Zinnat/Ceftin</i>	42	3	22	17	81	5	43	33
ONCOLOGY AND EMESIS	213	162	33	18	420	320	65	35
<i>Zofran</i>	165	130	21	14	326	258	41	27
<i>Hycamtin</i>	28	18	8	2	55	35	16	4
OTHER	257	18	80	159	497	35	154	308
<i>Zantac</i>	55	16	13	26	107	31	25	51
	5,136	2,610	1,427	1,099	9,950	5,061	2,765	2,124

Pharmaceutical turnover includes co-promotion income. US dollar amounts shown above are a convenience translation of the sterling amounts.

BALANCE SHEET
At 31st December 2006

	31st December 2006 £m	31st December 2006 \$m
ASSETS		
Non-current assets		
Property, plant and equipment	6,930	13,583
Goodwill	758	1,486
Other intangible assets	3,293	6,454
Investments in associates and joint ventures	295	578
Other investments	441	864
Deferred tax assets	2,123	4,161
Other non-current assets	721	1,413
Total non-current assets	14,561	28,539
Current assets		
Inventories	2,437	4,776
Current tax recoverable	186	365
Trade and other receivables	5,317	10,421
Liquid investments	1,035	2,029
Cash and cash equivalents	2,005	3,930
Assets held for sale	12	23
Total current assets	10,992	21,544
TOTAL ASSETS	25,553	50,083
LIABILITIES		
Current liabilities		
Short-term borrowings	(718)	(1,407)
Trade and other payables	(4,871)	(9,547)
Current tax payable	(621)	(1,217)
Short-term provisions	(1,055)	(2,068)
Total current liabilities	(7,265)	(14,239)
Non-current liabilities		
Long-term borrowings	(4,772)	(9,353)
Deferred tax provision	(595)	(1,166)
Pensions and other post-employment benefits	(2,339)	(4,584)
Other provisions	(528)	(1,035)
Other non-current liabilities	(406)	(796)
Total non-current liabilities	(8,640)	(16,934)
TOTAL LIABILITIES	(15,905)	(31,173)
NET ASSETS	9,648	18,910
EQUITY		
Share capital	1,498	2,936
Share premium account	858	1,682
Other reserves	65	127
Retained earnings	6,965	13,651
Shareholders' equity	9,386	18,396
Minority interests	262	514
TOTAL EQUITY	9,648	18,910

US dollar amounts shown above are a convenience transaction of the sterling amounts using the period end rate of £1/\$1.96.